HLF Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Herbalife Ltd (HLF) is not a strong buy for a beginner, long-term investor at this moment. While the stock has some positive momentum in analyst ratings and price targets, the technical indicators, financial performance, and lack of significant catalysts suggest a cautious approach. The stock's recent financial performance shows declining profitability, and there are no proprietary trading signals or significant trading trends to justify immediate action. Holding off for now is recommended.
The MACD is negative and expanding (-0.298), indicating bearish momentum. RSI is neutral at 21.447, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the stock is trading below its pivot level of 18.383, with key support at 16.691 and resistance at 20.075. Overall, the technical indicators suggest a mixed trend with no strong buy signal.
Analyst upgrades from Citi and Maxim, with increased price targets and positive outlooks on the company's momentum and sustainable business model. Revenue growth of 6.26% YoY in Q4 2025 is also a positive indicator.
Declining net income (-52.00% YoY) and EPS (-53.45% YoY) in Q4 2025, along with a slight drop in gross margin (-0.40% YoY). MACD is bearish, and there is no significant news or trading trends to drive the stock higher. Regulatory concerns and competitive pressures remain risks.
In Q4 2025, revenue increased by 6.26% YoY to $1.283 billion. However, net income dropped by 52.00% YoY to $85.4 million, and EPS fell by 53.45% YoY to $0.81. Gross margin also declined slightly to 77.53%. Overall, the company's profitability metrics are weakening despite revenue growth.
Recent analyst ratings are mixed but leaning positive. Citi raised its price target to $21 and maintained a Buy rating, citing strong Q4 results and momentum. Maxim initiated coverage with a Buy rating and a $20 price target, highlighting a sustainable business model. However, BofA maintained an Underperform rating with a price target of $9, citing weak fundamentals and macroeconomic uncertainties.
